# A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

> **NCT04521023** · PHASE4 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 132 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Cantabell Tab
- **DRUG:** Candemore Plus Tab

## Key facts

- **NCT ID:** NCT04521023
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2020-01-28
- **Final completion:** 2020-06-03
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521023, "A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04521023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*